Activation of M₁ and M₄ muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia

References

• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• BorroniBCostanziCPadovaniAGenetic susceptibility to behavioural and psychological symptoms in Alzheimer diseaseCurr Alzheimer Res20107215816419715553
   PubMed Web of Science ®Google Scholar
• SarterMLustigCTaylorSFCholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatmentsNeuropharmacology20126231544155321156184
   PubMed Web of Science ®Google Scholar
• DaviesPMaloneyAJSelective loss of central cholinergic neurons in Alzheimer’s diseaseLancet197628000140363862
   PubMed Web of Science ®Google Scholar
• MesulamMMMufsonEJWainerBHLeveyAICentral cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1–Ch6)Neuroscience1983104118512016320048
   PubMed Web of Science ®Google Scholar
• TalyACorringerPJGuedinDLestagePChangeuxJPNicotinic receptors: allosteric transitions and therapeutic targets in the nervous systemNat Rev Drug Discov20098973375019721446
   PubMed Web of Science ®Google Scholar
• BatschNLMittelmanMSWorld Alzheimer Report 2012: Overcoming the Stigma of DementiaLondonAlzheimer’s Disease International2012 Available from: http://www.alz.co.uk/research/WorldAlzheimerReport2012.pdfAccessed. January 6, 2013
   Google Scholar
• GrossbergGTDiagnosis and treatment of Alzheimer’s diseaseJ Clin Psychiatry200364 Suppl 93612934967
   PubMed Web of Science ®Google Scholar
• HardyJAHigginsGAAlzheimer’s disease: the amyloid cascade hypothesisScience199225650541841851566067
   PubMed Web of Science ®Google Scholar
• SelkoeDJThe molecular pathology of Alzheimer’s diseaseNeuron1991644874981673054
   PubMed Web of Science ®Google Scholar
• BraakHBraakENeuropathological stageing of Alzheimer-related changesActa Neuropathol19918242392591759558
   PubMed Web of Science ®Google Scholar
• WoolfNJThe critical role of cholinergic basal forebrain neurons in morphological change and memory encoding: a hypothesisNeurobiol Learn Mem19966632582668946420
   PubMed Web of Science ®Google Scholar
• BartusRTDeanRL3rdBeerBLippaASThe cholinergic hypothesis of geriatric memory dysfunctionScience198221745584084147046051
   PubMed Web of Science ®Google Scholar
• WhitehousePJPriceDLStrubleRGClarkAWCoyleJTDelonMRAlzheimer’s disease and senile dementia: loss of neurons in the basal forebrainScience19822154537123712397058341
   PubMed Web of Science ®Google Scholar
• PazzagliAPepeuGAmnesic properties of scopolamine and brain acetylcholine in the ratInt J Neuropharmacol1965452912995893609
   PubMedGoogle Scholar
• RustedJMWarburtonDMThe effects of scopolamine on working memory in healthy young volunteersPsychopharmacology (Berl)19889621451523148139
   PubMed Web of Science ®Google Scholar
• SunderlandTTariotPNCohenRMWeingartnerHMuellerEA3rdMurphyDLAnticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response studyArch Gen Psychiatry19874454184263579494
   PubMed Web of Science ®Google Scholar
• BirksJCholinesterase inhibitors for Alzheimer’s diseaseCochrane Database Syst Rev20061CD00559316437532
   PubMed Web of Science ®Google Scholar
• Muñoz-TorreroDAcetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s diseaseCurr Med Chem200815242433245518855672
   PubMed Web of Science ®Google Scholar
• DelrieuJPiauACaillaudCVoisinTVellasBManaging cognitive dysfunction through the continuum of Alzheimer’s disease: role of pharmacotherapyCNS Drugs201125321322621323393
   PubMed Web of Science ®Google Scholar
• FeldmanHTreating Alzheimer’s disease with cholinesterase inhibitors: what have we learned so far?Int Psychogeriatr200214 Suppl 13512636177
   PubMed Web of Science ®Google Scholar
• KauferDBeyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer’s diseaseDement Geriatr Cogn Disord19989 Suppl 28149718229
   PubMed Web of Science ®Google Scholar
• RöslerMThe efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementiaInt J Clin Pract Suppl2002127203612139365
   PubMedGoogle Scholar
• BartenDMAlbrightCFTherapeutic strategies for Alzheimer’s diseaseMol Neurobiol2008372–317118618581273
   PubMed Web of Science ®Google Scholar
• BhugraDThe global prevalence of schizophreniaPLoS Med200525e151 ; quiz e175.15916460
   PubMed Web of Science ®Google Scholar
• AndreasenNCCarpenterWTJrDiagnosis and classification of schizophreniaSchizophr Bull19931921992148322032
   PubMed Web of Science ®Google Scholar
• TollefsonGDSangerTMLuYThiemeMEDepressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidolArch Gen Psychiatry19985532502589510219
   PubMed Web of Science ®Google Scholar
• WestermeyerJComorbid schizophrenia and substance abuse: a review of epidemiology and courseAm J Addict200615534535516966190
   PubMed Web of Science ®Google Scholar
• DavisKLKahnRSKoGDavidsonMDopamine in schizophrenia: a review and reconceptualizationAm J Psychiatry199114811147414861681750
   PubMed Web of Science ®Google Scholar
• SawaASnyderSHSchizophrenia: neural mechanisms for novel therapiesMol Med200391–23912765334
   PubMed Web of Science ®Google Scholar
• HillSKBishopJRPalumboDSweeneyJAEffect of second-generation antipsychotics on cognition: current issues and future challengesExpert Rev Neurother2010101435720021320
   PubMed Web of Science ®Google Scholar
• MurphyBPChungYCParkTWMcGorryPDPharmacological treatment of primary negative symptoms in schizophrenia: a systematic reviewSchizophr Res2006881–352516930948
   PubMed Web of Science ®Google Scholar
• LismanJECoyleJTGreenRWCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaTrends Neurosci200831523424218395805
   PubMed Web of Science ®Google Scholar
• MarinOInterneuron dysfunction in psychiatric disordersNat Rev Neurosci201213210712022251963
   PubMed Web of Science ®Google Scholar
• NoetzelMJJonesCKConnPJEmerging approaches for treatment of schizophrenia: modulation of glutamatergic signalingDiscov Med2012147833534323200065
   PubMed Web of Science ®Google Scholar
• ThakurathiNVincenziBHendersonDCAssessing the prospect of donepezil in improving cognitive impairment in patients with schizophreniaExpert Opin Investig Drugs2013222259265
   PubMed Web of Science ®Google Scholar
• OsterholmRKCamorianoJKTransdermal scopolamine psychosisJAMA19822472230817077797
   PubMed Web of Science ®Google Scholar
• BodickNCOffenWWLeveyAIEffects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer diseaseArch Neurol19975444654739109749
   PubMed Web of Science ®Google Scholar
• BodickNCOffenWWShannonHEThe selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer diseaseAlzheimer Dis Assoc Disord199711 Suppl 4S16S229339268
   PubMed Web of Science ®Google Scholar
• ShekharAPotterWZLightfootJSelective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophreniaAm J Psychiatry200816581033103918593778
   PubMed Web of Science ®Google Scholar
• ConnPJJonesCKLindsleyCWSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersTrends Pharmacol Sci200930314815519201489
   PubMed Web of Science ®Google Scholar
• BymasterFPCarterPAYamadaMRole of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activityEur J Neurosci20031771403141012713643
   PubMed Web of Science ®Google Scholar
• ConnPJChristopoulosALindsleyCWAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disordersNat Rev Drug Discov200981415419116626
   PubMed Web of Science ®Google Scholar
• NoetzelMJRookJMVinsonPNFunctional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system functionMol Pharmacol201281212013322021324
   PubMed Web of Science ®Google Scholar
• LeveyAIKittCASimondsWFPriceDLBrannMRIdentification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodiesJ Neurosci19911110321832261941081
   PubMed Web of Science ®Google Scholar
• HerschSMGutekunstCAReesHDHeilmanCJLeveyAIDistribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodiesJ Neurosci1994145 Pt 2335133638182478
   PubMed Web of Science ®Google Scholar
• GerberDJSotnikovaTDGainetdinovRRHuangSYCaronMGTonegawaSHyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient miceProc Natl Acad Sci U S A20019826153121531711752469
   PubMed Web of Science ®Google Scholar
• MarinoMJConnPJDirect and indirect modulation of the N-methyl D-aspartate receptorCurr Drug Targets CNS Neurol Disord20021111612769631
   PubMedGoogle Scholar
• MarinoMJRouseSTLeveyAIPotterLTConnPJActivation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cellsProc Natl Acad Sci U S A1998951911465114709736760
   PubMed Web of Science ®Google Scholar
• AnagnostarasSGMurphyGGHamiltonSESelective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant miceNat Neurosci200361515812483218
   PubMed Web of Science ®Google Scholar
• DavisAAFritzJJWessJLahJJLeveyAIDeletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivoJ Neurosci201030124190419620335454
   PubMed Web of Science ®Google Scholar
• SpaldingTATrotterCSkjaerbaekNDiscovery of an ectopic activation site on the M(1) muscarinic receptorMol Pharmacol20026161297130212021390
   PubMed Web of Science ®Google Scholar
• LangmeadCJFryVAForbesITProbing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1- butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonistMol Pharmacol200669123624616207821
   PubMed Web of Science ®Google Scholar
• BradleySRLamehJOhrmundLAC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal modelNeuropharmacology201058236537319835892
   PubMed Web of Science ®Google Scholar
• LangmeadCJAustinNEBranchCLCharacterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1Br J Pharmacol200815451104111518454168
   PubMed Web of Science ®Google Scholar
• VanoverKEVeinbergsIDavisREAntipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584Behav Neurosci2008122357057518513127
   PubMed Web of Science ®Google Scholar
• HeinrichJNButeraJACarrickTPharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonistsEur J Pharmacol20096051–3535619168056
   PubMed Web of Science ®Google Scholar
• JonesCKBradyAEDavisAANovel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in ratsJ Neurosci20082841104221043318842902
   PubMed Web of Science ®Google Scholar
• KaneAThe In Vivo Characterization of TBPB, a Novel Allosteric Agonist of M1 Muscarinic Receptors: Implications for the Role of the M1 Muscarinic Receptor in Treatment of Schizophrenia [undergraduate thesis]Nashville (TN)Vanderbilt University2008
   Google Scholar
• DigbyGJNoetzelMJBubserMNovel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal modelsJ Neurosci201232258532854422723693
   PubMed Web of Science ®Google Scholar
• LeboisEPBridgesTMLewisLMDiscovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous systemACS Chem Neurosci20101210412121961051
   PubMed Web of Science ®Google Scholar
• AvlaniVALangmeadCJGuidaEOrthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptorMol Pharmacol20107819410420413650
   PubMed Web of Science ®Google Scholar
• DigbyGJUtleyTJLamsalAChemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding modeACS Chem Neurosci20123121025103623259038
   PubMed Web of Science ®Google Scholar
• GregoryKJSextonPMChristopoulosAAllosteric modulation of muscarinic acetylcholine receptorsCurr Neuropharmacol20075315716719305798
   PubMed Web of Science ®Google Scholar
• WoottenDChristopoulosASextonPMEmerging paradigms in GPCR allostery: implications for drug discoveryNat Rev Drug Discov201312863064423903222
   PubMed Web of Science ®Google Scholar
• DavieBJChristopoulosAScammellsPJDevelopment of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsACS Chem Neurosci2013471026104823659787
   PubMed Web of Science ®Google Scholar
• NathanPJWatsonJLundJThe potent M(1) receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunctionInt J Neuropsychopharmacol201316472173122932339
   PubMed Web of Science ®Google Scholar
• MaLSeagerMAWittmannMSelective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiationProc Natl Acad Sci U S A200910637159501595519717450
   PubMed Web of Science ®Google Scholar
• ShireyJKBradyAEJonesPJA selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learningJ Neurosci20092945142711428619906975
   PubMed Web of Science ®Google Scholar
• MillerEKCohenJDAn integrative theory of prefrontal cortex functionAnnu Rev Neurosci20012416720211283309
   PubMed Web of Science ®Google Scholar
• ChambonCJatzkeCWegenerNGraviusADanyszWUsing cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communicationEur J Pharmacol20126971–3738023085025
   PubMed Web of Science ®Google Scholar
• ChambonCWegenerNGraviusADanyszWA new automated method to assess the rat recognition memory: validation of the methodBehav Brain Res2011222115115721421012
   PubMed Web of Science ®Google Scholar
• KudukSDBeshoreDCNovel M(1) allosteric ligands: a patent reviewExpert Opin Ther Pat201222121385139823092292
   PubMed Web of Science ®Google Scholar
• ReidPRBridgesTMShefflerDJDiscovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probeBioorg Med Chem Lett20112192697270121194936
   PubMed Web of Science ®Google Scholar
• TarrJCTurlingtonMLReidPRTargeting selective activation of M(1) for the treatment of Alzheimer’s disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169ACS Chem Neurosci201231188489523173069
   PubMed Web of Science ®Google Scholar
• ThrelfellSClementsMAKhodaiTStriatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatumJ Neurosci20103093398340820203199
   PubMed Web of Science ®Google Scholar
• UkaiMOkudaAMamiyaTEffects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in miceEur J Pharmacol20044922–318318715178363
   PubMed Web of Science ®Google Scholar
• JonesCKEberleELShawDBMcKinzieDLShannonHEPharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in ratsJ Pharmacol Exp Ther200531231055106315574685
   PubMed Web of Science ®Google Scholar
• RasmussenTFink-JensenASauerbergPThe muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidanceSchizophr Res2001491–219320111343877
   PubMed Web of Science ®Google Scholar
• WattMLRorick-KehnLShawDBThe muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtypeNeuropsychopharmacology Epub822013
   Web of Science ®Google Scholar
• GomezaJZhangLKostenisEEnhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout miceProc Natl Acad Sci U S A19999618104831048810468635
   PubMed Web of Science ®Google Scholar
• JeonJDenckerDWörtweinGA subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviorsJ Neurosci20103062396240520147565
   PubMed Web of Science ®Google Scholar
• DenckerDWörtweinGWeikopPInvolvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomelineJ Neurosci201131165905590821508215
   PubMed Web of Science ®Google Scholar
• ChanWYMcKinzieDLBoseSAllosteric modulation of the muscarinic M4 receptor as an approach to treating schizophreniaProc Natl Acad Sci U S A200810531109781098318678919
   PubMed Web of Science ®Google Scholar
• ShireyJKXiangZOrtonDAn allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmissionNat Chem Biol200841425018059262
   PubMed Web of Science ®Google Scholar
• BradyAEJonesCKBridgesTMCentrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsJ Pharmacol Exp Ther2008327394195318772318
   PubMed Web of Science ®Google Scholar
• LeachKLoiaconoREFelderCCMolecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic propertiesNeuropsychopharmacology201035485586919940843
   PubMed Web of Science ®Google Scholar
• SuratmanSLeachKSextonPFelderCLoiaconoRChristopoulosAImpact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptorBr J Pharmacol201116271659167021198541
   PubMed Web of Science ®Google Scholar